surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData, a data and analytics company. Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback